Biotechnology Companies By Pe Ratio

Price To Earning
Price To EarningEfficiencyMarket RiskExp Return
1AMRN Amarin PLC
590.0
(0.06)
 3.01 
(0.19)
2ARWR Arrowhead Pharmaceuticals
482.39
(0.13)
 3.01 
(0.39)
3EVO Evotec SE ADR
444.0
 0.09 
 5.75 
 0.54 
4ENTA Enanta Pharmaceuticals
366.13
(0.20)
 2.51 
(0.51)
5GILD Gilead Sciences
359.42
 0.19 
 1.42 
 0.27 
6VCEL Vericel Corp Ord
357.33
 0.10 
 3.08 
 0.31 
7CAMP CAMP4 THERAPEUTICS PORATION
318.57
(0.21)
 8.53 
(1.75)
8XOMAP XOMA Corp
292.32
 0.07 
 0.76 
 0.05 
9XOMAO XOMA Corporation
288.41
 0.10 
 0.40 
 0.04 
10URGN UroGen Pharma
239.57
(0.08)
 2.89 
(0.24)
11BMRN Biomarin Pharmaceutical
220.73
(0.19)
 2.55 
(0.48)
12PSTX Poseida Therapeutics
214.0
(0.01)
 4.87 
(0.06)
13NBIX Neurocrine Biosciences
202.9
(0.09)
 2.91 
(0.25)
14ICCC ImmuCell
195.0
 0.02 
 2.68 
 0.05 
15XRTX XORTX Therapeutics
170.67
 0.06 
 18.38 
 1.05 
16SNDX Syndax Pharmaceuticals
126.11
(0.08)
 4.09 
(0.31)
17ARCT Arcturus Therapeutics Holdings
119.5
(0.07)
 4.10 
(0.28)
18SILO Silo Pharma
118.39
(0.12)
 4.98 
(0.61)
19IONS Ionis Pharmaceuticals
101.16
(0.17)
 2.65 
(0.45)
20FGEN FibroGen
97.67
 0.03 
 6.50 
 0.21 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit. Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.